BioCentury | Oct 14, 2019
Financial News

Mogrify raises $16M, outlines plans to advance cell therapy platform

After raising $16 million in the first close of a series A round, Mogrify unveiled more of its cell therapy pipeline and laid out goals to enhance its cell reprogramming platform. Existing investor Ahren Innovation...
BioCentury | Apr 25, 2019
Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
BioCentury | May 30, 2016
Financial News

DefiniGEN completes venture financing

DefiniGEN Ltd. , Cambridge, U.K. Business: Supply/Service Date completed: 2016-05-23 Type: Venture financing Raised: L1.5 million ($2.2 million) Investors: Cambridge Enterprise; 24Haymarket; Providence Investment; Parkwalk Advisors; Camber Capital Management; company director WIR Staff...
BioCentury | Jun 9, 2014
Financial News

DefiniGEN Ltd. financial update

DefiniGEN raised £1 million ($1.7 million) in the final close of a series A round, bringing the total raised in the round to £2.3 million ($3.8 million). Cambridge Enterprise and 24Haymarket led the round. LBA;...
BioCentury | Feb 25, 2013
Financial News

Sphere Fluidics completes venture financing

Sphere Fluidics Ltd. , Cambridge, U.K. Business: Gene/Cell therapy Date completed: 2/20/13 Type: Venture financing Raised: $2.5 million Investors: 24Haymarket; Royal Society; Cambridge Enterprise; Providence Investment; University of Cambridge; London Business Angels; angel investors WIR Staff...
Items per page:
1 - 5 of 5
BioCentury | Oct 14, 2019
Financial News

Mogrify raises $16M, outlines plans to advance cell therapy platform

After raising $16 million in the first close of a series A round, Mogrify unveiled more of its cell therapy pipeline and laid out goals to enhance its cell reprogramming platform. Existing investor Ahren Innovation...
BioCentury | Apr 25, 2019
Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
BioCentury | May 30, 2016
Financial News

DefiniGEN completes venture financing

DefiniGEN Ltd. , Cambridge, U.K. Business: Supply/Service Date completed: 2016-05-23 Type: Venture financing Raised: L1.5 million ($2.2 million) Investors: Cambridge Enterprise; 24Haymarket; Providence Investment; Parkwalk Advisors; Camber Capital Management; company director WIR Staff...
BioCentury | Jun 9, 2014
Financial News

DefiniGEN Ltd. financial update

DefiniGEN raised £1 million ($1.7 million) in the final close of a series A round, bringing the total raised in the round to £2.3 million ($3.8 million). Cambridge Enterprise and 24Haymarket led the round. LBA;...
BioCentury | Feb 25, 2013
Financial News

Sphere Fluidics completes venture financing

Sphere Fluidics Ltd. , Cambridge, U.K. Business: Gene/Cell therapy Date completed: 2/20/13 Type: Venture financing Raised: $2.5 million Investors: 24Haymarket; Royal Society; Cambridge Enterprise; Providence Investment; University of Cambridge; London Business Angels; angel investors WIR Staff...
Items per page:
1 - 5 of 5